A randomized, double-blind, placebo controlled, parallel group, multi-center study, to assess the safety and tolerability of 28 days treatment with NVA237 (100 or 200µg once a day) in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD)
Laufzeit: 01.01.2007 - 31.12.2009